JP2010513526A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010513526A5 JP2010513526A5 JP2009542935A JP2009542935A JP2010513526A5 JP 2010513526 A5 JP2010513526 A5 JP 2010513526A5 JP 2009542935 A JP2009542935 A JP 2009542935A JP 2009542935 A JP2009542935 A JP 2009542935A JP 2010513526 A5 JP2010513526 A5 JP 2010513526A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- tetrac
- cancer
- nanoparticles
- nanoparticle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- PPJYSSNKSXAVDB-UHFFFAOYSA-N 3,3',5,5'-tetraiodothyroacetic acid Chemical compound IC1=CC(CC(=O)O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 PPJYSSNKSXAVDB-UHFFFAOYSA-N 0.000 claims description 40
- 239000002105 nanoparticle Substances 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 24
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 11
- -1 cisplatinum Chemical compound 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 9
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 229940127089 cytotoxic agent Drugs 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 238000002651 drug therapy Methods 0.000 claims description 5
- 229920002307 Dextran Polymers 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 229920000954 Polyglycolide Polymers 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 claims description 4
- 230000035572 chemosensitivity Effects 0.000 claims description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
- 229960004316 cisplatin Drugs 0.000 claims description 4
- 229960004679 doxorubicin Drugs 0.000 claims description 4
- 229960005420 etoposide Drugs 0.000 claims description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical class C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 125000006239 protecting group Chemical group 0.000 claims description 4
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims description 4
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- 229920000936 Agarose Polymers 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 2
- 108091006905 Human Serum Albumin Chemical class 0.000 claims description 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical class C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 108010077895 Sarcosine Proteins 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 229940009456 adriamycin Drugs 0.000 claims description 2
- 125000003158 alcohol group Chemical group 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 claims description 2
- 210000000270 basal cell Anatomy 0.000 claims description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 2
- 229960001467 bortezomib Drugs 0.000 claims description 2
- 230000005907 cancer growth Effects 0.000 claims description 2
- 239000000679 carrageenan Substances 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 229940113118 carrageenan Drugs 0.000 claims description 2
- 239000001913 cellulose Chemical class 0.000 claims description 2
- 229920002678 cellulose Chemical class 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 229920006228 ethylene acrylate copolymer Polymers 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 229940014144 folate Drugs 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- 125000000524 functional group Chemical group 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 claims description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 230000001394 metastastic effect Effects 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000000914 phenoxymethylpenicillanyl group Chemical class CC1(S[C@H]2N([C@H]1C(=O)*)C([C@H]2NC(COC2=CC=CC=C2)=O)=O)C 0.000 claims description 2
- 229920001432 poly(L-lactide) Chemical class 0.000 claims description 2
- 229920000729 poly(L-lysine) polymer Chemical class 0.000 claims description 2
- 108010054442 polyalanine Proteins 0.000 claims description 2
- 229920000768 polyamine Polymers 0.000 claims description 2
- 229920000767 polyaniline Polymers 0.000 claims description 2
- 239000004626 polylactic acid Substances 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 108010011723 polytryptophan Proteins 0.000 claims description 2
- 108010033949 polytyrosine Proteins 0.000 claims description 2
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims description 2
- 229940043230 sarcosine Drugs 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 229940063683 taxotere Drugs 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 229960000303 topotecan Drugs 0.000 claims description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 235000005039 Brassica rapa var. dichotoma Nutrition 0.000 claims 1
- 244000130745 brown sarson Species 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 22
- 239000000463 material Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87677006P | 2006-12-22 | 2006-12-22 | |
| US92211307P | 2007-04-05 | 2007-04-05 | |
| US93622307P | 2007-06-18 | 2007-06-18 | |
| US95900607P | 2007-07-09 | 2007-07-09 | |
| US96701607P | 2007-08-30 | 2007-08-30 | |
| US99489507P | 2007-09-21 | 2007-09-21 | |
| US26207P | 2007-10-23 | 2007-10-23 | |
| US393507P | 2007-11-20 | 2007-11-20 | |
| PCT/US2007/026167 WO2008140507A2 (en) | 2006-12-22 | 2007-12-21 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010513526A JP2010513526A (ja) | 2010-04-30 |
| JP2010513526A5 true JP2010513526A5 (https=) | 2012-02-09 |
Family
ID=39832482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009542935A Withdrawn JP2010513526A (ja) | 2006-12-22 | 2007-12-21 | 甲状腺ホルモン類縁体、拮抗剤および製剤のためのナノ粒子及び重合体製剤ならびにその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9289395B2 (https=) |
| EP (1) | EP2120913B1 (https=) |
| JP (1) | JP2010513526A (https=) |
| AU (1) | AU2007353426A1 (https=) |
| CA (1) | CA2673133C (https=) |
| ES (1) | ES2535005T3 (https=) |
| WO (1) | WO2008140507A2 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071134B2 (en) | 2003-09-15 | 2011-12-06 | Ordway Research Institute, Inc. | Thyroid hormone analogs and methods of use |
| AU2004273986B2 (en) | 2003-09-15 | 2010-04-22 | Nanopharmaceuticals Llc | Thyroid hormone analogs and methods of use in angiogenesis |
| US9198887B2 (en) | 2003-09-15 | 2015-12-01 | Nanopharmaceuticals Llc | Thyroid hormone analogs and methods of use |
| US8668926B1 (en) | 2003-09-15 | 2014-03-11 | Shaker A. Mousa | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof |
| US9498536B2 (en) | 2005-09-15 | 2016-11-22 | Nanopharmaceuticals Llc | Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders |
| US10130686B2 (en) | 2005-09-15 | 2018-11-20 | Nanopharmaceuticals Llc | Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders |
| US20100209382A1 (en) | 2005-09-16 | 2010-08-19 | Ordway Research Institute, Inc. | Polyphenol Conjugates as RGD-Binding Compounds and Methods of Use |
| AU2007353426A1 (en) | 2006-12-22 | 2008-11-20 | Albany College Of Pharmacy And Health Sciences | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof |
| US20100159021A1 (en) * | 2008-12-23 | 2010-06-24 | Paul Davis | Small Molecule Ligands of the Integrin RGD Recognition Site and Methods of Use |
| US9180107B2 (en) | 2009-03-31 | 2015-11-10 | Nanopharmaceuticals Llc | Combination treatment of cancer with cetuximab and tetrac |
| CA2765792C (en) * | 2009-06-17 | 2017-03-28 | Nanopharmaceuticals Llc | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof |
| US8802240B2 (en) | 2011-01-06 | 2014-08-12 | Nanopharmaceuticals Llc | Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells |
| WO2012176212A1 (en) | 2011-06-20 | 2012-12-27 | V.B. Medicare Pvt. Ltd. | Carrier based nanogel formulation for skin targeting. |
| WO2013033513A1 (en) | 2011-08-31 | 2013-03-07 | University Of Georgia Research Foundation, Inc. | Apoptosis-targeting nanoparticles |
| WO2013096596A1 (en) * | 2011-12-20 | 2013-06-27 | Latham Keith R | Sustained drug release and improved product stability using non-covalent particle coating methods |
| EP2814496B1 (en) | 2012-02-17 | 2018-04-11 | University Of Georgia Research Foundation, Inc. | Nanoparticles for mitochondrial trafficking of agents |
| EP2662079A1 (en) | 2012-05-10 | 2013-11-13 | Ordway Research Institute, Inc. | Uses of formulations of thyroid hormone antagonists and nanoparticulate forms thereof to increase chemosensivity and radiosensitivity in tumor or cancer cells |
| US9271951B2 (en) | 2012-12-21 | 2016-03-01 | Mylan Inc. | Levothyroxine formulation with acacia |
| AU2013368945B2 (en) * | 2012-12-26 | 2020-01-23 | Innosign B.V. | Assessment of cellular signaling pathway activity using linear combination(s) of target gene expressions |
| WO2015074050A1 (en) | 2013-11-18 | 2015-05-21 | Nanopharmaceuticals Llc | Methods for screening patients for resistance to angioinhibition, treatment and prophylaxis thereof |
| US9950003B2 (en) | 2013-12-12 | 2018-04-24 | Technion Research & Development Foundation Ltd. | Pectin based nanoparticles |
| WO2015138992A1 (en) | 2014-03-14 | 2015-09-17 | University Of Georgia Research Foundation, Inc. | Mitochondrial delivery of 3-bromopyruvate |
| JP7074749B2 (ja) * | 2016-06-07 | 2022-05-24 | ナノファーマシューティカルズ エルエルシー | αｖβ３インテグリン甲状腺アンタゴニストにコンジュゲートした非開裂性ポリマー |
| US20190160139A1 (en) * | 2017-09-13 | 2019-05-30 | Massachusetts Institute Of Technology | Genotype-directed local delivery of targeted therapeutics |
| US11351137B2 (en) | 2018-04-11 | 2022-06-07 | Nanopharmaceuticals Llc | Composition and method for dual targeting in treatment of neuroendocrine tumors |
| US10328043B1 (en) | 2018-04-11 | 2019-06-25 | Nanopharmaceuticals, Llc. | Composition and method for dual targeting in treatment of neuroendocrine tumors |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| US10961204B1 (en) | 2020-04-29 | 2021-03-30 | Nanopharmaceuticals Llc | Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors |
| US11723888B2 (en) | 2021-12-09 | 2023-08-15 | Nanopharmaceuticals Llc | Polymer conjugated thyrointegrin antagonists |
| WO2025245015A1 (en) * | 2024-05-20 | 2025-11-27 | Regents Of The University Of Minnesota | Thyroid hormone prodrugs and compositions comprising the same |
Family Cites Families (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3625214A (en) | 1970-05-18 | 1971-12-07 | Alza Corp | Drug-delivery device |
| IL51354A (en) | 1977-01-28 | 1979-07-25 | Ames Yissum Ltd | Assay method for the quantitative determination of a hapten in aqueous solution |
| US4906474A (en) | 1983-03-22 | 1990-03-06 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
| US4650751A (en) | 1983-04-29 | 1987-03-17 | Technicon Instruments Corporation | Protected binding assay avoiding non-specific protein interference |
| US4719182A (en) | 1985-03-18 | 1988-01-12 | Eastman Kodak Company | Fluorescent labels and labeled species and their use in analytical elements and determinations |
| US4789734A (en) | 1985-08-06 | 1988-12-06 | La Jolla Cancer Research Foundation | Vitronectin specific cell receptor derived from mammalian mesenchymal tissue |
| US4801575A (en) | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| EP0545913B1 (en) | 1986-08-18 | 1999-02-24 | Emisphere Technologies, Inc. | Delivery systems for pharmacological agents |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5231000A (en) | 1987-10-08 | 1993-07-27 | The Mclean Hospital | Antibodies to A4 amyloid peptide |
| IT1216687B (it) * | 1988-04-01 | 1990-03-08 | Boehringer Biochemia Srl | Complessi di platino (ii), loro preparazione e impiego come antitumorali. |
| US4968590A (en) | 1988-04-08 | 1990-11-06 | Stryker Corporation | Osteogenic proteins and polypeptides |
| US5011486A (en) | 1988-11-18 | 1991-04-30 | Brown University Research Foundation | Composite nerve guidance channels |
| US5635482A (en) | 1989-08-14 | 1997-06-03 | The Regents Of The University Of California | Synthetic compounds and compositions with enhanced cell binding |
| US5438126A (en) | 1989-09-11 | 1995-08-01 | Arch Development Corporation | Human thyroid hormone receptor DNA |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5158978A (en) | 1990-02-05 | 1992-10-27 | British Technology Group (U.S.A.) | Thyroid hormone treatment of acute cardiovascular compromise |
| US5410016A (en) | 1990-10-15 | 1995-04-25 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
| US5773574A (en) | 1990-12-03 | 1998-06-30 | The Scripps Research Institute | Polypeptides for promoting cell attachment |
| US5766635A (en) | 1991-06-28 | 1998-06-16 | Rhone-Poulenc Rorer S.A. | Process for preparing nanoparticles |
| US5591709A (en) | 1991-08-30 | 1997-01-07 | Life Medical Sciences, Inc. | Compositions and methods for treating wounds |
| US5225204A (en) | 1991-11-05 | 1993-07-06 | Chen Jivn Ren | Stable dosage of levothyroxine sodium and process of production |
| WO1993024476A1 (en) | 1992-06-04 | 1993-12-09 | Clover Consolidated, Limited | Water-soluble polymeric carriers for drug delivery |
| US5482719A (en) | 1992-10-30 | 1996-01-09 | Guillet; James E. | Drug delivery systems |
| US5571840A (en) | 1993-06-22 | 1996-11-05 | The Regents Of The University Of Michigan | Method for treating central nervous system ischemia |
| US5593688A (en) | 1993-06-25 | 1997-01-14 | Nexstar Pharmaceuticals, Inc. | Liposomal targeting of ischemic tissue |
| EP0831769B2 (en) | 1995-06-07 | 2008-07-23 | Lavin, Dr., Thomas N. | Novel uses for thyroid hormones or thyroid hormone-like compounds |
| CN1126589A (zh) | 1995-06-09 | 1996-07-17 | 中国科学院成都有机化学研究所 | 一种激素缓释微囊注射剂及其制备方法 |
| FR2742357B1 (fr) | 1995-12-19 | 1998-01-09 | Rhone Poulenc Rorer Sa | Nanoparticules stabilisees et filtrables dans des conditions steriles |
| US6596712B2 (en) | 1996-04-26 | 2003-07-22 | Genaera Corporation | Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities |
| US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
| DE69837968D1 (de) | 1997-01-30 | 2007-08-02 | Univ Technology Corp | Diagnose und behandlung myocardieller fehler |
| US6207665B1 (en) | 1997-06-12 | 2001-03-27 | Schering Aktiengesellschaft | Piperazine derivatives and their use as anti-inflammatory agents |
| US5994309A (en) | 1997-07-25 | 1999-11-30 | Angstrom Pharmaceuticals, Inc. | Anti-invasive and anti-angiogenic compositions and methods |
| US6414037B1 (en) | 1998-01-09 | 2002-07-02 | Pharmascience | Pharmaceutical formulations of resveratrol and methods of use thereof |
| US6482406B1 (en) | 1999-03-26 | 2002-11-19 | Duncan J. Stewart | Cell-based gene therapy for the pulmonary system |
| US6022901A (en) | 1998-05-13 | 2000-02-08 | Pharmascience Inc. | Administration of resveratrol to prevent or treat restenosis following coronary intervention |
| KR19990085365A (ko) * | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| CA2333975A1 (en) | 1998-06-04 | 1999-12-09 | Mount Sinai School Of Medicine | Method of inhibiting angiogenesis and tumor growth and preventing tumor growth and metastases |
| CA2246791A1 (en) | 1998-09-01 | 2000-03-01 | Alison Buchan | Treatment of endothelium with somatostatin analogues |
| US6521593B1 (en) | 1999-02-01 | 2003-02-18 | Childrens Hospital Los Angeles | Methods for inhibiting brain tumor growth |
| US6740680B1 (en) * | 1999-04-26 | 2004-05-25 | Becton Pharma, Inc. | Pharmaceutical compositions to tetrac and methods of use thereof |
| EP1173163B1 (en) | 1999-04-26 | 2006-06-21 | Elliot Danforth, Jr. | Pharmaceutical compositions of tetrac and methods of use thereof |
| US6776984B1 (en) | 1999-08-20 | 2004-08-17 | George R. Schwartz | Induced regeneration and repair of damaged neurons and nerve axon myelin |
| US6531580B1 (en) | 1999-06-24 | 2003-03-11 | Ixsys, Inc. | Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same |
| JP5704780B2 (ja) | 1999-08-13 | 2015-04-22 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 脈管形成因子の用量および心筋血流を改善するための投与方法 |
| WO2001036351A2 (en) | 1999-11-19 | 2001-05-25 | Corvas International, Inc. | Plasminogen activator inhibitor antagonists related applications |
| EP1267935A2 (en) | 2000-01-12 | 2003-01-02 | Light Sciences Corporation | Novel treatment for eye disease |
| FI107018B (fi) | 2000-04-06 | 2001-05-31 | Ipsat Therapies Oy | Dermatologinen käyttö ja valmiste |
| ES2344831T3 (es) | 2000-06-23 | 2010-09-08 | Mitsubishi Tanabe Pharma Corporation | Potenciadores de un efecto antitumoral. |
| EP1296666A2 (en) | 2000-07-06 | 2003-04-02 | Delsys Pharmaceutical Corporation | Improved thyroid hormone formulations |
| JP2004528278A (ja) | 2000-12-18 | 2004-09-16 | ボード オブ レジェンツ，ザ ユニバーシティー オブ テキサス システム | インサイチュヒドロゲルを用いた、局所領域の化学療法および放射線治療 |
| US6534676B2 (en) | 2001-01-31 | 2003-03-18 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same |
| CA2440394C (en) * | 2001-05-07 | 2011-10-04 | Cornell Research Foundation, Inc. | Biodegradable copolymers linked to segment with a plurality of functional groups |
| US6645526B2 (en) | 2001-11-13 | 2003-11-11 | Mylan Pharmaceuticals, Inc. | Storage stable thyroxine active drug formulations and methods for their production |
| US6821947B2 (en) | 2001-12-04 | 2004-11-23 | Thomas Jefferson University | Endorepellin: methods and compositions for inhibiting angiogenesis |
| JP2005511713A (ja) | 2001-12-07 | 2005-04-28 | ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア | 加齢性黄斑変性についての処置 |
| US6720008B2 (en) | 2002-01-22 | 2004-04-13 | Pr Pharmaceuticals, Inc. | Composition and method for the encapsulation of water-soluble molecules into nanoparticles |
| CA2478317A1 (en) | 2002-03-04 | 2003-09-18 | Medimmune, Inc. | Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate |
| WO2003084470A2 (en) | 2002-04-02 | 2003-10-16 | Arizeke Pharmaceuticals, Inc. | Compositions and methods for targeted biological delivery of molecular carriers |
| EP1354953A1 (en) | 2002-04-17 | 2003-10-22 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Smac-peptides as therapeutics against cancer and autoimmune diseases |
| US20040024749A1 (en) | 2002-08-01 | 2004-02-05 | Omega Systems, Inc. | Automated system and method for reviewing medical and financial claim records and for identifying missing devices and/or services associated with medical and financial procedures |
| EP1422311B1 (en) | 2002-11-19 | 2007-02-28 | Hitachi Tool Engineering Ltd. | Hard film and hard film coated tool |
| US20070037739A1 (en) | 2003-02-03 | 2007-02-15 | Medlogics Device Corporation | Compounds useful in coating stents to prevent and treat stenosis and restenosis |
| AU2004208962B2 (en) | 2003-02-10 | 2010-07-15 | To-Bbb Holding B.V. | Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions |
| US9149440B2 (en) | 2003-09-02 | 2015-10-06 | University Of South Florida | Nanoparticles for drug-delivery |
| US8668926B1 (en) | 2003-09-15 | 2014-03-11 | Shaker A. Mousa | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof |
| US9198887B2 (en) | 2003-09-15 | 2015-12-01 | Nanopharmaceuticals Llc | Thyroid hormone analogs and methods of use |
| AU2004273986B2 (en) | 2003-09-15 | 2010-04-22 | Nanopharmaceuticals Llc | Thyroid hormone analogs and methods of use in angiogenesis |
| US8071134B2 (en) | 2003-09-15 | 2011-12-06 | Ordway Research Institute, Inc. | Thyroid hormone analogs and methods of use |
| US20050158376A1 (en) | 2003-10-23 | 2005-07-21 | Sardi William F. | Dietary supplement and method of processing same |
| US7407973B2 (en) | 2003-10-24 | 2008-08-05 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
| EP1708689A2 (en) | 2003-12-29 | 2006-10-11 | The President and Fellows of Harvard College | Compositions for treating or preventing obesity and insulin resistance disorders |
| US20080193377A1 (en) | 2004-06-28 | 2008-08-14 | University Of Maryland, Baltimore | Radiolabeled Nanohybrids Targeting Solid Tumor Neovasculature and Method of Using Same |
| US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
| JP2008513461A (ja) * | 2004-09-15 | 2008-05-01 | オードウェイ リサーチ インスティテュート | 血管形成を促進する甲状腺ホルモンアナログ |
| US20060166303A1 (en) | 2005-01-24 | 2006-07-27 | Eberhard Spanuth | Use of cardiac hormones for assessing a cardiovascular risk with respect to the administration of anti-inflammatory drugs |
| EP2314614B1 (en) | 2005-02-28 | 2015-11-25 | Sangamo BioSciences, Inc. | Anti-angiogenic methods and compositions |
| DE602006008625D1 (de) | 2005-04-01 | 2009-10-01 | Intezyne Technologies Inc | Polymermicellen für die arzneistoffzufuhr |
| US20090022806A1 (en) | 2006-12-22 | 2009-01-22 | Mousa Shaker A | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof |
| US20100209382A1 (en) | 2005-09-16 | 2010-08-19 | Ordway Research Institute, Inc. | Polyphenol Conjugates as RGD-Binding Compounds and Methods of Use |
| CA2648243C (en) * | 2006-04-11 | 2015-12-22 | Shaker A. Mousa | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof |
| CA2655411A1 (en) | 2006-06-15 | 2007-12-21 | Biogen Idec Ma Inc. | Combination therapy employing lymphotoxin beta receptor binding molecules in combination with second agents |
| AU2007353426A1 (en) | 2006-12-22 | 2008-11-20 | Albany College Of Pharmacy And Health Sciences | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof |
| EP2231669A1 (en) | 2008-01-09 | 2010-09-29 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Phosphodiesterase inhibitors |
| US20100159021A1 (en) | 2008-12-23 | 2010-06-24 | Paul Davis | Small Molecule Ligands of the Integrin RGD Recognition Site and Methods of Use |
| US9180107B2 (en) | 2009-03-31 | 2015-11-10 | Nanopharmaceuticals Llc | Combination treatment of cancer with cetuximab and tetrac |
| CA2765792C (en) | 2009-06-17 | 2017-03-28 | Nanopharmaceuticals Llc | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof |
| WO2011149595A1 (en) | 2010-05-28 | 2011-12-01 | Nexgen Dermatologics, Inc. | Combination therapy for skin disorders |
| US8802240B2 (en) | 2011-01-06 | 2014-08-12 | Nanopharmaceuticals Llc | Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells |
-
2007
- 2007-12-21 AU AU2007353426A patent/AU2007353426A1/en not_active Abandoned
- 2007-12-21 CA CA2673133A patent/CA2673133C/en not_active Expired - Fee Related
- 2007-12-21 EP EP07874182.4A patent/EP2120913B1/en not_active Not-in-force
- 2007-12-21 WO PCT/US2007/026167 patent/WO2008140507A2/en not_active Ceased
- 2007-12-21 JP JP2009542935A patent/JP2010513526A/ja not_active Withdrawn
- 2007-12-21 ES ES07874182.4T patent/ES2535005T3/es active Active
-
2010
- 2010-11-16 US US12/947,389 patent/US9289395B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010513526A5 (https=) | ||
| Han et al. | Orally deliverable nanotherapeutics for the synergistic treatment of colitis-associated colorectal cancer | |
| Cheng et al. | Formulation of functionalized PLGA–PEG nanoparticles for in vivo targeted drug delivery | |
| Liang et al. | Terminal modification of polymeric micelles with π-conjugated moieties for efficient anticancer drug delivery | |
| Zhang et al. | PEG-farnesylthiosalicylate conjugate as a nanomicellar carrier for delivery of paclitaxel | |
| CN103030140A (zh) | 透明质酸修饰的氧化石墨烯及其药物组合物的制备方法与应用 | |
| Tao et al. | Synergistic breast tumor cell killing achieved by intracellular co-delivery of doxorubicin and disulfiram via core–shell–corona nanoparticles | |
| JP2015519330A5 (https=) | ||
| CN107335060A (zh) | 一类基于rgd多肽-化疗药物的小分子偶联物及其纳米前药系统 | |
| CN107375935B (zh) | 一种温度敏感型水凝胶纳米药物输送系统 | |
| Lei et al. | Co-delivery of paclitaxel and gemcitabine via a self-assembling nanoparticle for targeted treatment of breast cancer | |
| CN102319436A (zh) | 叶酸修饰的o-羧甲基壳聚糖-脱氧胆酸复合物及其制备方法与应用 | |
| US20190091152A1 (en) | Use of umirolimus and its derivatives for treating cancer | |
| CN103800915B (zh) | 一种靶向整合素受体的联合载药胶束及其制备方法 | |
| WO2020063419A1 (zh) | 一种聚酯-聚酯型生物可降解两亲性嵌段共聚物、其制备方法及应用 | |
| CN101869712A (zh) | 使用包囊抗肿瘤药物的聚合胶束用于治疗肿瘤的药物组合物 | |
| CN119212725A (zh) | 聚合物纳米聚集体药物组合物及其用途 | |
| CN101780042A (zh) | 一种紫杉醇纳米靶向缓释长循环脂质体及其制备方法 | |
| Zhou et al. | A linear polyethylenimine (LPEI) drug conjugate with reversible charge to overcome multidrug resistance in cancer cells | |
| JP2010504318A (ja) | ｐＨ標的化薬剤送達のための組成物及び方法 | |
| Hoskins et al. | In vitro and in vivo anticancer activity of a novel nano-sized formulation based on self-assembling polymers against pancreatic cancer | |
| CN110665009B (zh) | 一种促肿瘤血管正常化纳米化吉西他滨及其应用 | |
| CN103446040A (zh) | 一种包载多西紫杉醇的聚合物胶束及其制备方法 | |
| Zhang et al. | p-Hydroxybenzoic acid (p-HA) modified polymeric micelles for brain-targeted docetaxel delivery | |
| Shi et al. | Reduction-responsive and tumor-targeted polyprodrug nanocarriers for targeting therapy of hepatocellular carcinoma |